CTI.L Regulatory News (CTI)

Cathay International Holdings Limited

("Cathay" or the "Company")

Annual Information Update

Hong Kong, 21 May 2012 - Cathay International Holdings Limited (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC"), today submits its Annual Information Update which refers to information that has been published or made available to the public by the Company throughout the period from 21 May 2011 to 21 May 2012.

This Annual Information Update is required by and is being made in accordance with the requirements of Prospectus Rule 5.2 and not for any other purpose. It should be noted that:

- information is referred to in this update rather than included in full;

- information referred to in this update was up to date at the time it was published but some of this information may now be out of date; and the Company is under no obligation to update any such information;

- information referred to in this update may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction;

- this Annual Information Update does not constitute an offer of any securities addressed to any person and should not be relied on by any person.

1. Announcements made via a Regulatory Information Service

The following UK regulatory announcements have been made via a Regulatory Information Service. A copy of these announcements can be obtained from the London Stock Exchange website, http://www.londonstockexchange.com/exchange/prices-and-markets/stocks/exchange-insight/company-news.html?fourWayKey=BMG1965E1030GBGBXSSX3 and on the Cathay International Holdings website at www.cathay-intl.com.hk.

Date Headline

17 May 2012 Interim Management Statement

10 May 2012 License for collagen injectable filler

20 April 2012 Annual Report and Accounts

3 April 2012 Grant of Share Options

29 March 2012 Annual Results for the Year Ended 31 December 2011

19 March 2012 Notification of Annual Results

27 February 2012 Lansen received technology endorsement

9 January 2012 Lansen signs exclusive agreement

18 November 2011 Interim Management Statement

26 October 2011 Lansen signs exclusive agreement with Ethypharm

25 August 2011 Interim Results 2011

15 August 2011 Notification of Interim Results

2. As a company incorporated in Bermuda, the Company does not file returns with Companies House in the U.K. The Company has made the following filings with the Registrar of Companies in Bermuda:

Date Description of filing

23 November 2011 Annual Government Fee

12 September 2011 Annual Declaration of Business

3. Documents published and sent to shareholders

The following documents have been dispatched by the Company to its shareholders during period from 21 May 2011 to 21 May 2012. Copies of these documents can be obtained from the Company at the Company's offices at Suites 1203-4, 12/F., Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong.

Date Document

10 April 2012 Annual Report for the year ended 31 December 2011

10 April 2012 Notice of Annual General Meeting

31 August 2011 Interim Report 2011

For further enquiries, please contact:

About Cathay International Holdings Limited

Cathay International Holdings Limited (CTI.L) is an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC").

Taking advantage of the strong and growing domestic demand for high quality healthcare products in China, Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, China's leading specialty pharmaceutical company focused on rheumatology and Haotian Group, a company engaged in the manufacture, marketing and sale of key active ingredients for healthcare products, including dietary supplement inositol. To complement its healthcare portfolio, Cathay has a research and product development business focused on bringing new products to the growing Chinese market.

The Group employs more than 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a private equity investment arm focused on minority investment opportunities and a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.